Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report

Hematology

Volumn 14, Issue 4, 2009, Pages 224-226

  Bruserud, Øyvind ^a   Havardstein, Kathrine ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Immune thrombocytopenic purpura; Mycophenolate mofetil; Rituximab

Indexed keywords

DANAZOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

AGED; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; PRIORITY JOURNAL; RELAPSE; SPLENECTOMY; STEROID THERAPY; THROMBOCYTE COUNT; TREATMENT RESPONSE; BLOOD; DOSE RESPONSE; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYCOPHENOLIC ACID; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 70349916130     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X439782     Document Type: Article

References (10)

1. Godeau B, Bierling P. Treatment of idiopathic thrombocytopenic purpura in adults. Presse Med 2008; 37: 1292-1298.
2. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
3. Schweizer C, Reu FJ, Ho AD, Hensel M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007; 86: 711-717.
4. Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78:275-280.
5. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti- CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
6. Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Crit Rev Oncol Hematol 2008; 65: 21-31.
7. Hou M, Peng J, Shi Y et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 70: 353-357.
8. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81: 19-25.
9. Kotb R, Pinganaud C, Trichet C et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005; 75: 60-64.
10. Zhang W, Ji L, Cao X et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. APS 2005; 26: 598-602.